Expression enhancement in trastuzumab therapeutic monoclonal antibody production using genomic amplification with methotrexate

Avicenna Journal of Medical Biotechnology

Volumn 5, Issue 2, 2013, Pages 87-95

  Akbarzadeh Sharbaf, Soudabeh ^a   Yakhchali, Bagher ^a   Minuchehr, Zarrin ^a   Shokrgozar, Mohammad Ali ^b   Zeinali, Sirous ^b,c  

^a NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c Kawsar's Human Genetic Research Center   (Iran)

Author keywords

Dihydrofolate reductase (DHFR); Monoclonal antibody; Recombinant proteins; Trastuzumab

Indexed keywords

DIHYDROFOLATE REDUCTASE; METHOTREXATE; TRASTUZUMAB;

ANIMAL CELL; ANTIBODY PRODUCTION; ARTICLE; DRUG ACTIVITY; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE DOSAGE; HEAVY CHAIN; IMMUNOFLUORESCENCE; LIGHT CHAIN; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REAL TIME POLYMERASE CHAIN REACTION; RECOMBINANT DNA TECHNOLOGY; WESTERN BLOTTING;

EID: 84875311479     PISSN: 20082835     EISSN: 20084625     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58(13):2825-2831.
2. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18(13):2241-2251.
3. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6(5):343-357.
4. Zhang H, Richter M, Greene MI. Therapeutic monoclonal antibodies for the ErbB family of receptor tyrosine kinases. Cancer Biol Ther 2003;2 (4 Suppl 1):S122-126.
5. Ross JS, Gray K, Gray GS, Worland PJ, Rolfe M. Anticancer antibodies. Am J Clin Pathol 2003;119 (4):472-485.
6. Drebin JA, Link VC, Weinberg RA, Greene MI. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci USA 1986;83(23):9129-9133.
7. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an antip185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89(10):4285-4289.
8. Slamon DJ, Romond EH, Perez EA. Advances in adjuvant therapy for breast cancer. Clin Adv Hematol Oncol 2006;4(3 Suppl 7):suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl.
9. Katsumata M, Okudaira T, Samanta A, Clark DP, Drebin JA, Jolicoeur P, et al. Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat Med 1995;1(7):644-648.
10. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr., Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673--1684.
11. Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, Sims P, et al. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J Immunol Methods 2002;263(1-2):133-147.
12. Xiong H, Ran Y, Xing J, Yang X, Li Y, Chen Z. Expression vectors for human-mouse chimeric antibodies. J Biochem Mol Biol 2005;38(4):414-419.
13. Chusainow J, Yang YS, Yeo JH, Toh PC, Asvadi P, Wong NS, et al. A study of monoclonal antibody-producing CHO cell lines: what makes a stable high producer? Biotechnol Bioeng 2009;102 (4):1182-1196.
14. Xiong KH, Liang QC, Xiong H, Zou CX, Gao GD, Zhao ZW, et al. Expression of chimeric antibody in mammalian cells using dicistronic expression vector. Biotechnol Lett 2005;27(21):1713-1717.
15. Jiang Z, Huang Y, Sharfstein ST. Regulation of recombinant monoclonal antibody production in chinese hamster ovary cells: a comparative study of gene copy number, mRNA level, and protein expression. Biotechnol Prog 2006;22(1):313-318.
16. Liu W, Wei H, Liang S, Zhang J, Sun R, Tian Z. A balanced expression of two chains of heterodimer protein, the human interleukin-12, improves highlevel expression of the protein in CHO cells. Biochem Biophys Res Commun 2004;313(2):287-293.
17. Schlatter S, Stansfield SH, Dinnis DM, Racher AJ, Birch JR, James DC. On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells. Biotechnol Prog 2005;21(1):122-133.
18. Urlaub G, Kas E, Carothers AM, Chasin LA. Deletion of the diploid dihydrofolate reductase locus from cultured mammalian cells. Cell 1983;33(2): 405-412.
19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227(5259):680-685.
20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C(T)] method. Methods 2001;25(4):402-408.
21. Kim NS, Byun TH, Lee GM. Key determinants in the occurrence of clonal variation in humanized antibody expression of cho cells during dihydrofolate reductase mediated gene amplification. Biotechnology Prog 2001;17(1):69-75.
22. Lucas BK, Giere LM, DeMarco RA, Shen A, Chisholm V, Crowley CW. High-level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector. Nucleic Acids Res 1996;24(9):1774-1779.
23. Kim SJ, Lee GM. Cytogenetic analysis of chimeric antibody-producing CHO cells in the course of dihydrofolate reductase-mediated gene amplification and their stability in the absence of selective pressure. Biotechnol Bioeng 1999;64(6):741-749.
24. Mutskov V, Felsenfeld G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J 2004;23 (1):138-149.
25. Richards EJ, Elgin SC. Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. Cell 2002;108(4):489-500.
26. Grohs BM, Niu Y, Veldhuis LJ, Trabelsi S, Garabagi F, Hassell JA, et al. Plant-produced trastuzumab inhibits the growth of HER2 positive cancer cells. J Agric Food Chem 2010;58(18):10056-10063.
27. Yusibov V, Streatfield SJ, Kushnir N. Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Human Vaccin 2011;7(3):313-321.
28. Pikaart MJ, Recillas-Targa F, Felsenfeld G. Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators. Genes Dev 1998;12(18):2852-2862.